ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.
Enzalutamide delays metastasis in men with non-metastatic castration̶resistant prostate cancer (CRPC) without worsening health-related quality of life (HRQoL) and significantly decreases the... Read More
New findings support the safety of including selected men with Gleason 3+4 prostate cancer in active surveillance (AS) programs, Australian researchers reported... Read More
The authors of a recent prostate cancer study claim that a drug manufacturer and the US Food and Drug Administration... Read More
The Prostate Cancer Prevention Trial (PCPT) showed that the use of finasteride, a 5-alpha-reductase inhibitor, for 7 years reduced the... Read More
Adding mitoxantrone and prednisone (MP) to adjuvant androgen-deprivation therapy (ADT) does not improve overall survival (OS) or disease-free survival (DFS)... Read More
Circulating tumor cell (CTC) counts correspond with overall survival (OS) among patients with early-phase metastatic castration-resistant prostate cancer (mCRPC), according to a study... Read More
The majority of patients with metastatic castration-resistant prostate cancer (CRPC) have evidence of bone metastases. Among available bone-targeted therapies, only radium-223 dichloride... Read More
Enzalutamide may not increase the incidence of seizure among patients with metastatic castration-resistant prostate cancer (mCRPC) and seizure risk factors,... Read More
Caucasian and African American patients with prostate cancer who are insured privately may have different clinical outcomes, but these disparities are less... Read More
Reduced-dose cabazitaxel is non-inferior to the standard dose for patients with metastatic castration-resistant prostate cancer (mCRPC) who previously received docetaxel, according to... Read More
